10-Q: Immunic Inc. Reports Q1 2025 Results, Cites Concerns Over Going Concern

Immunic Inc. reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern without additional funding.

Summary

• Immunic Inc. reported a net loss of $25.47 million for the three months ended March 31, 2025, compared to a net loss of $29.58 million for the same period in 2024.
• The company's research and development expenses increased to $21.53 million from $18.74 million year-over-year.
• As of March 31, 2025, Immunic had cash and cash equivalents of $14.3 million.
• The company states that it does not have adequate liquidity to fund its operations for the next twelve months without raising additional capital, raising substantial doubt about its ability to continue as a going concern.
• Immunic is focused on developing oral immunology therapies for chronic inflammatory and autoimmune diseases.
• The company's lead drug candidate, vidofludimus calcium (IMU-838), is in Phase 3 clinical development for relapsing multiple sclerosis (RMS).
• Immunic announced positive data from its Phase 2 CALLIPER trial of vidofludimus calcium in patients with primary progressive multiple sclerosis (PMS), showing a 30% reduction in the relative risk of disability worsening.
• The company is preparing for Phase 2 clinical testing of IMU-856 in patients with ongoing active celiac disease (OACD).
• Immunic completed an equity offering in April 2025, raising approximately $4.6 million in net proceeds.
• The company's accumulated deficit as of March 31, 2025, was approximately $536.9 million.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. Positive clinical data is offset by financial concerns and the need for additional funding. The going concern warning significantly lowers the sentiment.

Positives

• Vidofludimus calcium showed a 30% reduction in the relative risk of disability worsening in PMS patients in the Phase 2 CALLIPER trial.
• IMU-856 demonstrated a dose-dependent increase of glucagon-like peptide-1 (GLP-1) levels in a Phase 1b clinical trial in celiac disease patients.
• The company completed an equity offering in April 2025, raising approximately $4.6 million in net proceeds.
• The IDMC confirmed that the predetermined futility criteria have not been met and recommending that both ENSURE trials should continue without changes, including no need for a potential increase of the sample size.

Negatives

• Immunic reported a net loss of $25.47 million for Q1 2025.
• The company's cash and cash equivalents stood at $14.3 million as of March 31, 2025.
• Immunic expresses substantial doubt about its ability to continue as a going concern due to insufficient liquidity.
• The company has an accumulated deficit of approximately $536.9 million as of March 31, 2025.

Risks

• The company's ability to continue as a going concern is dependent on securing additional funding.
• Delays in clinical trials could negatively impact the company's development programs.
• Failure of clinical trials to meet their endpoints could result in the termination of development programs.
• Failure to obtain regulatory approval for product candidates would prevent the company from generating revenue from product sales.
• The company's future expenses and capital requirements are difficult to forecast and will depend on many factors, including the timing and structure of any strategic options and transactions, if any.

Future Outlook

Immunic expects to continue to incur significant expenses and increasing operating losses for the foreseeable future as it continues the development of its product candidates. The company's ability to continue as a going concern is dependent on securing additional funding.

Management Comments

• Management believes that vidofludimus calcium, with combined neuroprotective, anti-inflammatory, and antiviral effects as well as a favorable safety and tolerability profile, has the potential to be a unique treatment option targeted to the complex pathophysiology of MS.
• Management believes that IMU-856 may represent a unique treatment approach, as the mechanism of action targets the restoration of the intestinal barrier function and bowel wall architecture in patients suffering from gastrointestinal diseases.

Industry Context

The biotechnology industry is characterized by high levels of risk and uncertainty, particularly in the clinical development phase. Immunic's focus on oral immunology therapies aligns with a growing trend towards more convenient and patient-friendly treatment options for chronic inflammatory and autoimmune diseases. The company's lead drug candidate, vidofludimus calcium, is targeting a large and competitive market for multiple sclerosis treatments.

Comparison to Industry Standards

• Many comparable biotechnology companies, such as Biogen, Novartis, and Roche, are also heavily invested in developing treatments for multiple sclerosis and other autoimmune diseases.
• Immunic's approach of developing orally administered small molecule therapies is similar to that of other companies in the industry, such as Celgene (now part of Bristol Myers Squibb).
• The company's cash runway is shorter than that of many of its larger competitors, which could limit its ability to advance its development programs.
• The 30% reduction in the relative risk of disability worsening in PMS patients observed in the Phase 2 CALLIPER trial is a promising result, but further studies are needed to confirm these findings.

Legal Proceedings

• The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows.

Related Party Transactions

• On August 29, 2024, Immunic, Inc. and Dr. Duane Nash entered into Addendum Number 6 to the Executive Chairman Agreement to extend the term of Dr. Nashs employment as Executive Chairman of the Board of Directors of the Company to December 31, 2025.
• In connection with Addendum Number 6, the Company will increase Dr. Nashs monthly base salary in 2025 to $33,986 from $32,368 (which includes the cash retainer payable for serving on the Companys Board or for acting as the Chairman of the Board)

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees face uncertainty due to the company's financial situation.
• Patients may benefit from the successful development of the company's product candidates.
• Creditors face increased risk due to the company's going concern warning.

Next Steps

• Executing the ongoing Phase 3 ENSURE clinical trials of vidofludimus calcium in RMS.
• Completing the analysis of the full data set of the Phase 2 CALLIPER clinical trial and discussing the results with healthcare authorities to determine appropriate next steps for vidofludimus calcium in PMS.
• Executing the IMU-856 development program, including preparation of a Phase 2 clinical trial.
• Continuing preclinical research to complement the existing clinical activities, explore additional indications for potential future development and generating additional molecules for potential future development.
• Facilitating readiness for potential commercial launch of our product candidates through targeted and stage-appropriate pre-commercial activities.
• Evaluating potential strategic collaborations for each product candidate in order to complement our existing research and development capabilities and to facilitate potential commercialization of these product candidates by taking advantage of the resources and capabilities of strategic collaborators in order to enhance the potential and value of each product candidate.

Key Dates

Keywords

Immunic, vidofludimus calcium, IMU-838, IMU-856, IMU-381, multiple sclerosis, ulcerative colitis, celiac disease, clinical trials, biotechnology, autoimmune diseases, inflammatory diseases, going concern, equity offering, net loss